A recent study has shown that third-generation HER2-specific CAR-T cells can efficiently eliminate GBM cells in vitro and that the activity of the administered CAR-T cells is increased by their combination with programmed cell death protein 1 blockade [27]. This evidence concerns the gene ERBB2 and glioblastoma.